Apricus Biosciences (APRI) Reports Completion of Transfer of Vitaros German Marketing Authorization
- S&P, Dow open flat as Middle East jitters ease, Netflix weighs on Nasdaq
- Sony/Apollo bid for Paramount could be worth as much as $29 billion - Source
- Netflix Q1 earnings top estimates on blowout subscriber growth
- Stocks off two-month low as fear of Middle East escalation eases
- Gold prices rally past $2,400 on reports of Israel strikes on Iran
- Tritium DCFC Limited (DCFC): Three Australian subsidiaries were determined to be insolvent or likely to become insolvent
- Hasbro (HAS) Announces Resignation of Cynthia Williams, President of Wizards of the Coast and Hasbro Gaming
- Frontier Communications (FYBR) says third party had gained unauthorized access to portions of its information technology environment
- Ibotta (IBTA) Prices 6.56M Share IPO at $88/sh
- Netflix (NFLX) Tops Q1 EPS by 77c, Offers Guidance
- Netflix, Tesla, Amex, P&G fall premarket; Paramount Global gains
- After-hours movers: Netflix, Intuitive Surgical, Nordstrom, KB Home
- Midday movers: Tesla, Blackstone, Las Vegas Sands fall; DR Horton rises
- After-hours movers: Alcoa rises; Equifax and Las Vegas Sands fall
- Midday movers: Travelers, JB Hunt fall; United Airlines rises
Apricus Biosciences Announces Completion of Transfer of VitarosĀ® German Marketing Authorization to Ferring Pharmaceuticals
August 10, 2016 7:00 AM EDTSAN DIEGO, Aug. 10, 2016 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq: APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that Ferring Pharmaceuticals, the Companys new partner in Germany, has received the German marketing authorization for Vitaros®.
We are pleased that the transfer of the German marketing authorization to Ferring, a critical step in Ferrings plan to re-launch Vitaros in this important market, has been completed, said Richard Pascoe, Chief Executive Officer of Apricus. Moreover, this marks the first in a series of marketing authorization... More